Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Hikma And Glenmark’s Ryaltris Break-Up Illustrates Shifts In Strategies
Hikma Hands US Rights Back To Glenmark, Which Will Market Directly
Apr 07 2026
•
By
Dave Wallace
and
Anju Ghangurde
Glenmark and Hikma have ended their US commercialization deal on Ryaltris
(Shutterstock)
More from Deals
More from Business